This Article Full Text Full Text (PDF) All Versions of this Article: 28/6/1151    most recent ATVBAHA.108.164210v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Batenburg, W. W. Articles by Danser, A. H. J. Search for Related Content PubMed PubMed Citation Articles by Batenburg, W. W. Articles by Danser, A. H. J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Blood Pressure Medicines

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:1151.)
© 2008 American Heart Association, Inc.

Cell Biology and Signaling

Aliskiren-Binding Increases the Half Life of Renin and Prorenin in Rat Aortic Vascular Smooth Muscle Cells

Wendy W. Batenburg; René J.A. de Bruin; Jeanette M.G. van Gool; Dominik N. Müller; Michael Bader; Geneviève Nguyen; A. H. Jan Danser

From the Erasmus MC (W.W.B., R.J.A.d.B., J.M.G.v.G., A.H.J.D.), Rotterdam, The Netherlands; Max Delbrück Center for Molecular Medicine (D.N.M., M.B.), Berlin, Germany; and the Institut National de Santé et de la Recherche Médicale (Inserm) Unit 833 and Chaire de Médecine Expérimentale (G.N.), Collège de France, Paris, France.

Correspondence to Prof dr. A.H.J. Danser, PhD, Division of Vascular Pharmacology and Metabolism, room EE1418b, Department of Internal Medicine, Erasmus MC, Dr. Molewaterplein 50, 3015 GE Rotterdam, The Netherlands. E-mail a.danser{at}erasmusmc.nl

Objective— Renin inhibition with aliskiren has been reported to cause a greater rise in renin than other types of renin-angiotensin system blockade, thereby potentially leading to angiotensin generation or stimulation of the human (pro)renin receptor (h(P)RR). Here we studied whether this rise in renin is attributable to an aliskiren-induced change in the prorenin conformation, allowing its detection in renin assays, or a change in renin/prorenin clearance. We also investigated whether aliskiren affects (pro)renin binding to its receptors, using rat aortic vascular smooth muscle cells (VSMCs) overexpressing the h(P)RR.

Methods and Results— A 48-hour incubation with aliskiren at 4°C converted the prorenin conformation from "closed" to "open," thus allowing its recognition in active site-directed renin assays. VSMCs accumulated (pro)renin through binding to mannose 6-phosphate receptors (M6PRs) and h(P)RRs. Aliskiren did not affect binding at 4°C. At 37°C, aliskiren increased (pro)renin accumulation up to 40-fold, and M6PR blockade prevented this. Aliskiren increased the intracellular half life of prorenin 2 to 3 times.

Conclusion— Aliskiren allows the detection of prorenin as renin, and decreases renin/prorenin clearance. Both phenomena may contribute to the "renin" surge during aliskiren treatment, but because they depend on aliskiren binding, they will not result in angiotensin generation. Aliskiren does not affect (pro)renin binding to its receptors.

Renin inhibition with aliskiren causes a large rise in renin, potentially leading to angiotensin generation or stimulation of the (pro)renin receptor ((P)RR). This study shows that the renin rise relates to the detection of prorenin as renin and to a decrease in (pro)renin clearance. Aliskiren does not affect (pro)renin-(P)RR binding.

Key Words: prorenin • renin • aliskiren • half-life • receptor

This article has been cited by other articles:

				C. Cousin, D. Bracquart, A. Contrepas, P. Corvol, L. Muller, and G. Nguyen Soluble Form of the (Pro)Renin Receptor Generated by Intracellular Cleavage by Furin Is Secreted in Plasma Hypertension, June 1, 2009; 53(6): 1077 - 1082. [Abstract] [Full Text] [PDF]

				H.-H. Parving, B. M. Brenner, John. J. V. McMurray, D. de Zeeuw, S. M. Haffner, S. D. Solomon, N. Chaturvedi, M. Ghadanfar, N. Weissbach, Z. Xiang, et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design Nephrol. Dial. Transplant., May 1, 2009; 24(5): 1663 - 1671. [Abstract] [Full Text] [PDF]

				M. Krop, I. M. Garrelds, R. J.A. de Bruin, J. M.G. van Gool, N. D.L. Fisher, N. K. Hollenberg, and A.H. Jan Danser Aliskiren Accumulates in Renin Secretory Granules and Binds Plasma Prorenin Hypertension, December 1, 2008; 52(6): 1076 - 1083. [Abstract] [Full Text] [PDF]

				R. Dietz, R. Dechend, C.-M. Yu, M. Bheda, J. Ford, M. F. Prescott, and D. L. Keefe Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension1 Journal of Renin-Angiotensin-Aldosterone System, September 1, 2008; 9(3): 163 - 175. [Abstract] [PDF]

				W. W Batenburg and A. J. Danser Prorenin and the (pro)renin receptor: binding kinetics, signalling and interaction with aliskiren Journal of Renin-Angiotensin-Aldosterone System, September 1, 2008; 9(3): 181 - 184. [PDF]

				A. J. Danser and G. Nguyen Spotlight on Renin: The Renin Academy Summit: advancing the understanding of renin science Journal of Renin-Angiotensin-Aldosterone System, June 1, 2008; 9(2): 119 - 123. [PDF]